molnupiravir: Clinical Trials

30 trials of molnupiravir, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

17 completed, 8 recruiting, 3 unknown, 2 terminated. 11 Phase 2, 8 Phase 3, 7 Phase 1, 2 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 211Completed 5, Recruiting 5, Terminated 1
Phase 38Completed 4, Recruiting 2, Terminated 2
Phase 17Completed 6, Recruiting 1
Not applicable2Completed 2

Follow molnupiravir: new trials by email Literature Review of molnupiravir trials Research Report on molnupiravir

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Adaptive Dengue Antiviral Platform Trial
Molnupiravir 400 mg, VIS513 (a monoclonal antibody), Remdesivir 100mg - Dengue, Antiviral Drugs
Phase 2RecruitingOxford University Clinical Research Unit, Vietnam5002026-04-202026-09-28
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
Molnupiravir, Placebo - Coronavirus Disease (COVID-19)
Phase 3RecruitingMerck Sharp & Dohme LLC30822024-12-022026-11-06
Assessing Antiviral Treatments in Early Symptomatic RSV
Ribavirin, Molnupiravir, Favipiravir - Respiratory Syncytial Virus, Respiratory Syncytial Virus, Human
Phase 2RecruitingUniversity of Oxford10002024-07-252025-07-02
Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated With Experimental Influenza Virus (MK-4482-019)
Molnupiravir, Placebo molnupiravir, Placebo oseltamivir - Influenza Infection
Phase 1CompletedMerck Sharp & Dohme LLC1612023-08-212025-08-06
A Clinical Study of MK-4482 in Chinese Healthy Male Participants (MK-4482-009)
MK-4482 - Healthy
Phase 1CompletedMerck Sharp & Dohme LLC162023-06-282026-04-16
A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza
Oseltamivir, Favipiravir, Zanamivir - Influenza, Influenza, Human
Phase 2RecruitingUniversity of Oxford30002023-02-222026-04-14
A Study to Evaluate Molnupiravir Tablet Formulation Compared to the Molnupiravir Capsule Formulation in Healthy Adult Participants (MK-4482-011)
Molnupiravir - Healthy
Phase 1CompletedMerck Sharp & Dohme LLC642023-01-202025-07-11
Real World COVID-19 Antiviral Effectiveness Research
Oral Antiviral - COVID-19
UnknownClinical Research Centre, Malaysia6602022-12-062023-05-23
Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017)
Molnupiravir, Placebo, RSV A Memphis 37b - Respiratory Syncytial Virus
Phase 2CompletedMerck Sharp & Dohme LLC1162022-11-022025-07-18
A Randomised, Multi-centre, Double-blind, Phase 3 Study to Observe the Effectiveness, Safety and Tolerability of Molnupiravir Compared to Placebo Administered Orally to High-risk Adult Outpatients With Mild COVID-19 Receiving Local Standard of Care in South Africa
Molnupiravir 200 mg - COVID-19
Phase 2 / Phase 3CompletedUniversity of Witwatersrand, South Africa592022-08-122025-07-01
Effectiveness and Safety of New Oral Antivirals for COVID-19
Nirmatrelvir/ritonavir, Molnupiravir - COVID-19
UnknownUniversidade do Porto2112022-08-012023-12-18
Evaluation of the Efficacy and Safety of Molnupiravir Treatment in Mild/Moderate Covid-19 Patients.
Molnupiravir - COVID-19, SARS-CoV-2 Infection
UnknownSerap Yavuz26002022-07-072024-01-25
A Study to Evaluate Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment (MK-4482-003)
Molnupiravir - Renal Impairment
Phase 1CompletedMerck Sharp & Dohme LLC162022-06-292025-01-28
A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016)
Molnupiravir - Hepatic Impairment
Phase 1CompletedMerck Sharp & Dohme LLC142022-06-142025-01-28
Pharmacokinetics and Bioequivalence of Molnupiravir, 200 mg Capsules and Lagevrio, 200 mg Capsules in Healthy Volunteers
Molnupiravir - Viral Infection, COVID-19
Not applicableCompletedValenta Pharm JSC372022-04-222023-07-27
Pharmacokinetics, Safety and Efficacy Study of GP30341 (GEROPHARM, Russia)
GP30341 capsules 200 mg, Standard therapy - Pharmacokinetics, Safety Issues
Not applicableCompletedGeropharm2462022-03-172024-07-22
Molnupiravir and COVID-19 Mortality Reduction in the Omicron Era
Molnupiravir - COVID-19, SARS-CoV-2
CompletedCharles University, Czech Republic17955702022-01-012026-09-15
TURN-COVID Biobank: The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2
casirivimab with imdevimab, sotrovimab, molnupiravir - COVID-19
CompletedAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)11782021-12-142025-12-16
Open Multicenter Study for Assessment of Efficacy and Safety of Molnupiravir in Adult Patients With COVID-19
Molnupiravir (Esperavir), Standard of care - COVID-19
Phase 3CompletedPromomed, LLC2402021-12-012022-10-27
COVID-19 International Drug Pregnancy Registry
Antiviral Agents, Monoclonal antibody - Covid19
RecruitingPregistry20002021-12-012025-09-26

Showing 20 of 30. Sign in to see all of them.

Conditions studied

COVID-19 (20)  ·  Community-Acquired Pneumonia (1)  ·  Coronavirus Infections (1)  ·  Dengue (1)  ·  Influenza, Human (1)  ·  Pneumonia (1)  ·  Renal Insufficiency (1)  ·  Severe Acute Respiratory Syndrome (1)  ·  Virus Diseases (1)

Sponsors

Merck Sharp & Dohme LLC (10)  ·  University of Oxford (4)  ·  Ridgeback Biotherapeutics, LP (3)  ·  Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1)  ·  Charles University, Czech Republic (1)  ·  Clinical Research Centre, Malaysia (1)  ·  Geropharm (1)  ·  KU Leuven (1)  ·  Oxford University Clinical Research Unit, Vietnam (1)  ·  Pregistry (1)  ·  Promomed, LLC (1)  ·  Serap Yavuz (1)  ·  Universidade do Porto (1)  ·  University of Liverpool (1)  ·  University of Witwatersrand, South Africa (1)

Countries

United States (10)  ·  United Kingdom (8)  ·  Brazil (6)  ·  Russia (6)  ·  South Africa (6)  ·  France (5)  ·  Spain (5)  ·  Thailand (5)  ·  Colombia (4)  ·  Italy (4)  ·  Mexico (4)  ·  Philippines (4)  ·  Ukraine (4)  ·  Argentina (3)  ·  Japan (3)

Top investigators

Ashwin Balagopal, MD (1)  ·  Cheryl Renz, MD (1)  ·  Dmitriy Pushkar, Academician (1)  ·  Ee Vien Low, Ph.D. (1)  ·  Elizaveta Antonova (1)  ·  Francois WD Venter (1)  ·  Jim Bush, MBChB, PhD (1)  ·  Lubov Shpagina, MD (1)  ·  Peter W Horby (1)  ·  Saye Khoo (1)  ·  Sergey Noskov, MD, Pr. (1)

Results publications

PMID 33273742, PMID 34473343, PMID 39601078, PMID 32678530, PMID 33031652, PMID 33031764, PMID 33394942, PMID 33545096, PMID 33933206, PMID 34000257, PMID 34013969, PMID 34100024, PMID 34159342, PMID 34450619, PMID 34658014, PMID 34672950, PMID 34699618, PMID 34800427, PMID 34914868, PMID 35022711, PMID 35151397, PMID 35271729, PMID 35667065, PMID 35695334, PMID 35713300, PMID 35908569, PMID 35913747, PMID 36272432, PMID 36435798, PMID 36522698, PMID 36648627, PMID 36734509, PMID 36803992, PMID 37017631, PMID 37060915, PMID 37162745, PMID 37410460, PMID 37466374, PMID 37470445, PMID 37489818, PMID 37690669, PMID 37778363, PMID 37865101, PMID 37973784, PMID 37995070, PMID 38225598, PMID 38272046, PMID 38296965, PMID 38319178, PMID 38319179

NIH funding

2023 (1)